BioStock published an article on 3 June 2021 about Follicum, which can be read in full below. Many people’s hopes for Follicum’s hair loss project were dashed in May when the company presented top-line results demonstrating that the drug candidate FOL-005 did not show any significant effect compared to placebo. Hopes for the project were […]
Presentation BioStock Life Science Summit 2020, November 18
Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.
Read moreFollicum AB today announces that Jonas Edelswärd has been appointed as new CFO. He succeeds Fredrik...
Follicum AB (publ) today reports top-line data from a Phase IIa study of the tissue repairing peptid...
Follicum AB announces today that the company has recruited Dr. Kim Arvid Nielsen as new CEO, taking...
BioStock published an article on 3 June 2021 about Follicum, which can be read in full below. Many p...
BioStock published an article on 20 May 2021 about Follicum, which can be read in full below. Kim Ar...
BioStock published an article on 30 March 2021 about Follicum, which can be read in full below. Foll...
Follicum will attend the BIO International Convention Digital Event on 10-11 & 14-18 June 2021....
Follicum will attend the World Congress for Hair Research in Melbourne (WCHR), Australia, on 22-25 A...
